FindTrial
Sign In

A randomized double-blind controlled trial to assess the efficacy and safety of curcumin versus placebo in active rheumatoid arthritis patients

A randomized double-blind controlled trial to assess the efficacy and safety of curcumin versus placebo in active rheumatoid arthritis patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181115012
Enrollment
34
Registered
2018-11-15
Start date
2018-02-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active rheumatoid arthritis patients Rheumatoid arthritis

Interventions

Curcumin,Placebo
Active Comparator Drug,Placebo Comparator No treatment

Sponsors

Rheumatic Disease Unit, Department of Medicine
Lead Sponsor
Phramongkutklao college&#44
Collaborator
department of Medicine
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: RA (2010 ACR/EULAR criteria) Age ≥ 18 years old At least moderate disease activity (DAS 28 >3.2) VAS ≥ 50 Stable dose DMARDs therapy at least 1 month prior to randomization Inaccessible or denied add on therapy

Exclusion criteria

Exclusion criteria: Allergy to tumeric Pregnant or breast feeding Subjects with any current malignancy and on chemotherapy On anticoagulant

Design outcomes

Primary

MeasureTime frame
DAS-28 score 8 weeks Composite end point—

Secondary

MeasureTime frame
ACR 20 8 weeks Composite endpoint—

Countries

Thailand

Contacts

Public ContactJularat Tangsrisook

Phramongkutklao Hospital

jipjoie_13@icloud.com+66823994424

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026